Januvia (sitagliptin) / Ono Pharmaceutical, Merck (MSD) - LARVOL DELTA

Switching from sulfonylurea to sitagliptin among type 2 diabetic patients in combination with metformin or pioglitazone. (clinicaltrials.gov) - P=N/A | N=100 | Completed | Sponsor: Hokuriku Incretin-based Therapy Study Group | Unknown status ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy of Sitagliptin on glycaemic control in drug naïve patients with type 2 diabetes (STRICT-2) (clinicaltrials.gov) - P4 | N=300 | Completed | Sponsor: STRICT study Group | Unknown status ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy of Sitagliptin added to sulfonylurea in subjects with poorly controlled type 2 diabetes (STRICT-1) (clinicaltrials.gov) - P4 | N=200 | Completed | Sponsor: STRICT study Group | Unknown status ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative analysis of serious adverse effects of antidiabetic drugs and complications associated with type II diabetes mellitus. (PubMed, BMC Pharmacol Toxicol) - "Understanding the safety profiles of antidiabetic drugs is essential for optimizing treatment. The observed associations may help inform clinical decision-making and improve patient outcomes. However, they should be interpreted as associations rather than causal relationships and warrant further investigation in well-designed prospective studies."

Adverse events • Clinical • Journal • Observational data • Cardiovascular • CNS Disorders • Diabetes • Infectious Disease • Mental Retardation • Metabolic Disorders • Psychiatry • Retinal Disorders • Type 2 Diabetes Mellitus

GLP-1 Receptor Agonists Versus DPP-4 Inhibitors and 1-Year Outcomes in Inflammatory Bowel Disease With Type 2 Diabetes or Obesity: A Propensity-Matched Analysis (ACG 2026) - " Using the TriNetX Research Network of 111 healthcare organizations, we identified adults with Crohnâs disease or ulcerative colitis and T2DM or BMI â¥30 kg/m2 receiving GLP-1RA therapy (semaglutide, liraglutide, dulaglutide, or tirzepatide) or DPP-4i therapy (sitagliptin, linagliptin, saxagliptin, or alogliptin)... After matching, 11,720 GLP-1RA users were compared with 11,720 DPP-4i users. GLP-1RA use was associated with lower hospitalization (25.0% vs 31.4%; RR 0.80, 95% CI 0.76-0.83), mortality (3.1% vs 6.0%; RR 0.52, 95% CI 0.46-0.59), systemic corticosteroid initiation (14.4% vs 16.2%; RR 0.89, 95% CI 0.81-0.98), IBD-related bowel surgery (0.6% vs 1.0%; RR 0.61, 95% CI 0.45-0.81), C. difficile infection (1.0% vs 1.4%; RR 0.69, 95% CI 0.54-0.88), bowel obstruction (1.6% vs 2.1%; RR 0.78, 95% CI 0.64-0.95), and advanced IBD therapy initiation or escalation (2.0% vs 2.6%; RR 0.77, 95% CI 0.65-0.92). Gastroparesis did not differ (0.7% vs 0.8%; RR 0.89,..."

Crohn's disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • Ulcerative Colitis

GLP-1 Receptor Agonists vs DPP-4 Inhibitors and Cardiovascular Outcomes in Liver Transplant Recipients: A Propensity Score-Matched Active Comparator New-User Analysis of 3,606 Patients (ACG 2026) - "Adults with liver transplant status (Z94.4) and type 2 diabetes (E11.x) or obesity (E66.x) who were new users of GLP-1RA (semaglutide, dulaglutide, liraglutide, exenatide, tirzepatide) or DPP-4i (sitagliptin, saxagliptin, alogliptin, linagliptin) were identified using a 365-day washout for both drug classes... After matching, 1,803 pairs were identified. Post-match standardized mean differences were < 0.10 for all demographic and clinical covariates. GLP-1RA was associated with significantly lower 3-point MACE (HR 0.82, 95%CI 0.69â0.97, p=0.001)."

Clinical • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Obesity • Pancreatitis • Transplant Rejection • Transplantation • Type 2 Diabetes Mellitus

Reassessing GLP-1 Receptor Agonist Use in Gastrointestinal Motility Disorders: A Propensity-Matched Multicenter Study (ACG 2026) - "GLP-1 receptor agonist initiation was associated with lower risk of ED visit or hospitalization compared to sitagliptin (28.8% vs 33.3%; RR 0.865, 95% CI 0.779-0.962; p=0.007). New prokinetic prescription was also reduced (RR 0.721, 95% CI 0.540-0.962; p=0.025). Rates of new antiemetic prescription (RR 0.999, p=0.993), incident gastroparesis (RR 1.004, p=0.992), and new GERD or PPI initiation (RR 0.933, p=0.556) did not differ significantly."

Clinical • Constipation • Dyspepsia • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Obesity • Rare Diseases • Type 2 Diabetes Mellitus

Real-World Prescribing Patterns and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Empagliflozin-Sitagliptin-Metformin Fixed-Dose Combination Therapy. (PubMed, Cureus) - "Empagliflozin-based triple FDC therapy was prescribed among Indian patients with T2DM, particularly older adults with cardiometabolic comorbidities. Distinct prescribing patterns and clinical characteristics observed between ESM-25 and ESM-10 therapy may reflect individualized treatment selection in routine clinical practice."

Journal • Real-world evidence • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Variations and implications of Irisin, FGF-23, and N-MID osteocalcin in diabetic osteoporosis patients undergoing acarbose plus sitagliptin therapy: A prospective cohort analysis. (PubMed, J Med Biochem) - "Fracture prediction efficacy was markedly enhanced (AU C= 0.822) by combining the three indices, with statistical superiority over single-index analysis (P< 0.05). The combined detection of Irisin, FGF-23, and N-MID enables early detection of DOP while allowing for dynamic assessment of treatment outcomes and fracture risk."

Journal • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • FGF23

Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT03006172 Background: INAVO, a highly potent and selective PI3Kα inhibitor that also promotes degradation of mutated p110α, is approved by the FDA in combination with PALBO + fulvestrant (FULV) for PIK3CA-mutated, HR+, HER2–, endocrine-resistant advanced BC... Adults ≥ 18 years of age received INAVO alone (Arm A), + letrozole (LET) + PALBO (Arm B), + LET (Arm C), + FULV (Arm D), + FULV + PALBO (Arm E), or + FULV + PALBO + primary prophylactic metformin (Arm F)...The most common anti-HG medications were metformin (52.7%; biguanide; concomitant use in Arm F excluded), empagliflozin (25.5%; SGLT-2 inhibitor), sitagliptin (22.7%; DPP-4 inhibitor), and pioglitazone (13.6%; thiazolidinedione); insulin was used in 8.2% of pts... A high proportion of prediabetic/obese pts were included in GO39374. In most of these pts, HG was manageable with dose interruptions and oral anti-HG medications, most commonly metformin. Data support the use..."

Clinical • Combination therapy • Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Obesity • Oncology • Solid Tumor • HER-2 • PIK3CA

In Vitro Investigation of Sitagliptin on HaCaT Keratinocyte Migration and Proteomics Analysis for Wound Healing Applications. (PubMed, Eur J Pharmacol) - "Overall, sitagliptin enhances keratinocyte migration in association with changes in cytoskeletal and cell-adhesion-related proteins, although a direct causal relationship between these molecular changes and enhanced migration remains to be established. These findings provide preliminary evidence that, beyond glycemic control, sitagliptin may have therapeutic potential for wound healing applications to accelerate skin repair and tissue regeneration."

Journal • Preclinical • Diabetes • Metabolic Disorders • CTNNB1 • EGFR • ENKUR • FAM83H • ITGB1 • KRT16 • KRT17 • KRT5 • KRT6A

Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL) (clinicaltrials.gov) - P=N/A | N=25664 | Completed | Sponsor: Brigham and Women's Hospital | Active, not recruiting ➔ Completed

HEOR • Trial completion • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

Doxycycline in Type II Diabetes (clinicaltrials.gov) - P1/2 | N=60 | Completed | Sponsor: Mostafa Bahaa | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review. (PubMed, Endocr J) - "Oral sitagliptin and semaglutide were sequentially introduced; however, glycemic control remained suboptimal. In conclusion, once-weekly subcutaneous tirzepatide may be a therapeutic option for selected patients with pasireotide-induced hyperglycemia. However, further studies are needed to determine whether its effects differ from those of intensified GLP-1RA therapy."

Journal • Diabetes • Oncology • Pituitary Gland Carcinoma • SSTR • SSTR5

Cost-utility analysis of loxenatide versus DPP-4 inhibitors in Chinese patients with type 2 diabetes at high cardiovascular risk. (PubMed, Front Public Health) - "Assess the long-term cost-utility of loxenatide (0.2 mg once weekly) versus sitagliptin (100 mg once daily) in high cardiovascular risk type 2 diabetes patients in China inadequately controlled with metformin, from the healthcare system perspective. Loxenatide has a clear cost-utility advantage over sitagliptin in the treatment of Chinese patients with type 2 diabetes at high cardiovascular risk. These findings provide high-quality evidence to support clinical standardization, rational drug use, reimbursement policy decisions, and optimal allocation of healthcare resources for this patient population in China."

Clinical • HEOR • Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes. (PubMed, Obesity (Silver Spring)) - "In this high-risk population with type 2 diabetes, tirzepatide and injectable semaglutide offered comparable effectiveness in mitigating liver disease progression and MALO in the short- to medium-term follow-up."

Adverse events • Journal • Diabetes • Fibrosis • Genetic Disorders • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Oncology • Solid Tumor • Type 2 Diabetes Mellitus

Synthesis of Aminoacyl-2-Cyanopyrrolidine Compounds and Their Inhibitory Effect on the DPP-4 Enzyme. (PubMed, Pharmazie) - "Aminoacyl-2-cyanopyrrolidine derivatives bearing an imidazole or bis-cyanopyrrolidine structure are potent DPP-4 inhibitors. These findings highlight the importance of neighboring GLP-1 amino acid residues (positions 1 and 3) in inhibitor design. Further cellular and in vivo studies are warranted to evaluate the therapeutic potential of these compounds."

Journal • Diabetes • Metabolic Disorders

Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: Yonsei University

New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

Cardiovascular outcomes for dipeptidyl peptidase-4 inhibitors (DPP-4i) users compared to sulfonylurea (SU) users in a UK real-world dataset: an active comparator target trial framework (EASD 2026) - "DPP-4i use was associated with lower MACE risk than SU use in a real-world population with T2D. Risk reductions were observed in all subgroups but most pronounced among Black and Asian individuals. Given the neutral cardiovascular effect of sitagliptin vs placebo in TECOS, further analyses are needed to explore the effect of confounding factors such as baseline hypoglycaemia risk."

Clinical • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Endogenous glucose-dependent insulinotropic polypeptide attenuates postprandial cortisol responses in type 2 diabetes (EASD 2026) - P1 | "Materials and 12 participants with T2D (mean HbA1c 7.52 ± 0.11%) on metformin monotherapy received oral sitagliptin 100mg daily over one week, during which they attended the laboratory for two study days after an overnight fast. Endogenous GIP signalling does not influence circulating cortisol under fasting conditions but attenuates the cortisol response to intraduodenal glucose in T2D. These observations indicate a hitherto unrecognised interaction between GIP and cortisol secretion that has the potential to contribute to postprandial metabolic homeostasis."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The insulinotropic response to endogenous GIP in people with suboptimally controlled type 2 diabetes before and after 12 weeks of sitagliptin treatment (EASD 2026) - P1 | "Materials and Twelve participants with T2D (HbA1c 7.5 ± 0.1%) managed by diet or metformin monotherapy underwent 12 weeks sitagliptin therapy (100 mg daily). In people with T2D and slightly suboptimal glycaemic control, endogenous GIP contributes substantially to insulin secretion during hyperglycaemia. However, a modest improvement in glycaemic control does not further augment this effect. These findings highlight the importance of endogenous GIP signalling to the maintenance of glucose homeostasis in this subset of people with T2D."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients (clinicaltrials.gov) - P2/3 | N=80 | Completed | Sponsor: Beni-Suef University | Not yet recruiting ➔ Completed

Trial completion • Polyendocrine Metabolic Ovarian Syndrome

Dipeptidyl peptidase-4 inhibitors suppress myofibroblastic differentiation and hyaluronan synthesis in Graves' orbitopathy fibroblasts. (PubMed, Front Endocrinol (Lausanne)) - "The effects of linagliptin and sitagliptin on fibroblast proliferation, myofibroblastic differentiation, adipogenesis, and hyaluronan production were evaluated using DAPI nuclei counts, α-smooth muscle actin (α-SMA) immunofluorescence and Western blotting, Oil Red O staining, and ELISA, respectively. These findings provide in vitro evidence that DPP4i modulate selected orbital fibroblast phenotypes related to myofibroblastic differentiation and cytokine-induced hyaluronan production. Further mechanistic, pharmacokinetic, in vivo, and clinical studies are warranted to clarify their relevance to GO-related tissue remodeling."

Journal • Diabetes • Fibrosis • Immunology • Inflammation • Metabolic Disorders • Ophthalmology • Thyroid Eye Disease • Type 2 Diabetes Mellitus • DPP4 • IL1B • TGFB1

Gypenosides Induce Preadipocyte Browning via FXR/Rubicon Pathway-Mediated Inhibition of Autophagy. (PubMed, Chin J Integr Med) - "GPs activate FXR/Rubicon signal pathway to inhibit autophagy, inducing preadipocyte browning and offering a novel herbal-based anti-metabolic diseases strategy."

Journal • Genetic Disorders • Metabolic Disorders • Obesity • ATG7 • BECN1 • MAP1LC3B • PRDM16

Sitagliptin-associated Bullous Pemphigoid Complicated by Secondary Candidiasis, Urosepsis, and Gastrointestinal Bleeding in an Elderly Diabetic Woman. (PubMed, Ann Afr Med) - "Persistent dermatologic disease with markedly elevated immunoglobulin E levels necessitated omalizumab therapy, resulting in gradual improvement. Sitagliptin-associated BP should be considered in elderly diabetic patients presenting with blistering disorders after prolonged gliptin exposure. Early diagnosis, withdrawal of the suspected drug, histopathological confirmation, and multidisciplinary management are essential for favorable outcomes."

Journal • Bullous Pemphigoid • Candidiasis • Cardiovascular • Dermatology • Dermatopathology • Diabetes • Gastroenterology • Geriatric Disorders • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Pain • Type 2 Diabetes Mellitus